Healthed lecture series featuring Associate Professor Nigel Crawford
MVEC’s Associate Professor Nigel Crawford delivered the COVID-19 Update as part of the recent Healthed Australia online lecture series.
In this lecture, A/Prof Nigel Crawford discussed the following:
- An update on the latest ATAGI announcements
- Moderna safety data
- The booster debate
- Back to school
To listen to the lecture in full, click on the link below:
Healthed lecture series 28 September: COVID-19 Update
ATAGI statement about the need for additional doses of COVID-19 vaccines
The Australian Technical Advisory Group on Immunisation (ATAGI) has released a statement about the need for additional doses of COVID-19 vaccines.
The statement strongly recommends maximising first and second dose vaccine uptake across the community without delay in line with current prioritisation and outbreak response strategies and that two doses of any of the vaccines available in Australia have been shown to protect an individual from COVID-19 and its complications, as well as protecting the community.
ATAGI continues to closely monitor local and international data about the frequency and severity of COVID-19 in fully vaccinated individuals as well as reviewing the international data on the efficacy, effectiveness and safety of additional doses for specific high-risk patient populations, including immunocompromised individuals, and the population more generally. These data will inform future strategies regarding additional vaccine doses.
Additional doses can be defined as:
- Third doses: Additional COVID-19 doses required as part of the primary course to reach a comparable (optimal) level of protection
- Booster dose: Additional COVID-19 doses required at a broader population level, to optimise protection due to waning of immunity (loss of protection) over time, with booster doses also leading to improved immune memory.
To read the statement in full, please click the link below:
ATAGI statement about the need for additional doses of COVID-19 vaccines
Webinar recording now available: The Alfred community information session on COVID-19 vaccines
A webinar recording is now available from The Alfred’s community information session on COVID-19 vaccines which was held on Tuesday 21 September.
In this session, Allen Cheng and Associate Professor Nigel Crawford discuss in detail the COVID-19 vaccines, including the safety and efficacy in children over 12 years old, as well as answer questions from the community.
The full recording is available on The Alfred channels or the MVEC Facebook page via the links below:
The Alfred community discussion 21 September
MVEC Facebook page
ABC News: पांच से 11 साल के बच्चों के लिए इस्तेमाल होने वाली COVID-19 वैक्सीन के लिए मंजूरी के लिए आवेदन करेगी फाइजर
5 से 11 वर्ष की आयु के बच्चों के लिए Pfizer और BioNTech COVID-19 वैक्सीन की प्रभावशीलता और सुरक्षा का अध्ययन करने वाले 2,000 से अधिक बच्चों को शामिल करने वाले उच्च प्रत्याशित परीक्षण के शुरुआती परिणामों ने दिखाया है कि टीका सुरक्षित है और वायरस के खिलाफ एक मजबूत एंटीबॉडी प्रतिक्रिया स्थापित करता है।
प्रारंभिक आशाजनक परिणामों के बावजूद, यह अमेरिका और यहां ऑस्ट्रेलिया में 5 से 11 वर्ष की आयु के बच्चों के लिए टीकों के आधिकारिक रोलआउट से कुछ समय पहले होगा। एक बार परीक्षण का विश्लेषण पूरा हो जाने के बाद, अनुमोदन प्रदान करने के लिए, कंपनी को एफडीए को एक औपचारिक प्रतिरक्षा "ब्रिजिंग" अध्ययन प्रदान करने की आवश्यकता होती है, जो डेटा-आधारित साक्ष्य प्रदान करता है कि बच्चों ने वही एंटीबॉडी स्तर विकसित किए हैं जो पहले से ही सुरक्षात्मक साबित हुए हैं। बड़े बच्चों और किशोरों में। समीक्षा और आपातकालीन उपयोग प्राधिकरण के लिए परिणाम खाद्य एवं औषधि प्रशासन (एफडीए) को प्रस्तुत किए जाएंगे।
लेख को पूरा पढ़ने के लिए कृपया नीचे दिए गए लिंक पर क्लिक करें:
https://www.abc.net.au/news/2021-09-21/pfizer-covid-19-vaccine-5-to-11-year-old/100478362
ABC News: Israel is struggling with COVID-19, despite high vaccination rates. What lessons can Australia learn?
Due to an early and rapid vaccine roll-out, Israel was leading the way for COVID-19 immunisation, with nearly 80 per cent of its citizens aged 12 and over fully inoculated by June. However, cases numbers and rates of hospitalisations began to rapidly rise again by late June with Israel recording its highest single-day spike with 16,011 new infections on September 1.
As Australia works its way towards reopening, this article discusses the important lessons we can learn from Israel's vaccination program. Professor Lewin, Director of The Doherty Institute commented "What we've learned from [Israel], and what's consistent with the modelling is that even at 80 per cent, you need to have some public health measures in place to contain the transmission,"
लेख को पूरा पढ़ने के लिए कृपया नीचे दिए गए लिंक पर क्लिक करें:
ABC News: Israel is struggling with COVID-19, despite high vaccination rates. What lessons can Australia learn?
Commonwealth-funded places available for Nurse Immuniser course
There are limited places available for Registered Nurses (RNs) with one year of clinical experience to complete the Commonwealth-funded Nurse Immuniser short course free of charge (conditions apply).
The immunisation (Nurse immuniser) short course is based on the National Immunisation Education Framework for Health Professionals (2017) and has been accredited by the National body for health education Health Education Services Australia (HESA).
To find out more information on this course, please click on the links below. Please note some allocations have been exhausted.
The University of Melbourne: The immunisation (Nurse immuniser) short course
Benchmarque Group Immunisation Endorsement Pathway
एबीसी न्यूज: यूरोपीय संघ के सौदे के बाद ऑस्ट्रेलिया में एक और 10 लाख मॉडर्न कोविड-19 टीके की खुराक आ रही है
मॉडर्ना वैक्सीन की 1 मिलियन खुराकें जो यूरोपीय देशों से प्राप्त की गई हैं, इस सप्ताह देश भर में सामुदायिक फार्मेसियों को सीधे भेजी जानी हैं। यह घोषणा टीकाकरण पर ऑस्ट्रेलियाई तकनीकी सलाहकार समूह (ATAGI) की सलाह के अनुरूप है।
नवीनतम सौदे की घोषणा करने पर, सरकार ने पुष्टि की है कि अक्टूबर में एक टीके की पेशकश की प्रतीक्षा कर रहे सभी लोगों के लिए अब पर्याप्त टीका था। इसके अलावा, 20 सितंबर के सप्ताह से, देश भर में लगभग 1,800 सामुदायिक फार्मेसियों को मॉडर्ना की खुराक प्राप्त होगी, इसके बाद अतिरिक्त 1,800 को मॉडर्ना की खुराक प्राप्त होगी।
लेख को पूरा पढ़ने के लिए नीचे दिए गए लिंक पर क्लिक करें।
एबीसी न्यूज: यूरोपीय संघ के सौदे के बाद ऑस्ट्रेलिया में एक और 10 लाख मॉडर्न कोविड-19 टीके की खुराक आ रही है
The Age: ‘Jabba the Bus’ to take regional vaccination drive onto the road
Jabba the bus brings about exciting news for COVID-19 vaccination in regional Victoria. The mobile vaccine hub will deliver essential AstraZeneca and Pfizer vaccines to isolated residents of regional Victoria. The focus will be on the City of Greater Shepparton as well as Moira, Benalla, Strathbogie, Mitchell, Mansfield Murrindindi and Campaspe.
A high sense of urgency perpetuated the need for the mobile vaccination hub following a large COVID-19 outbreak in Shepparton which forced more than 20 000 people into isolation, including more than 500 staff from Goulburn Valley Health. Goulburn Valley Health Chief executive Matt Sharp indicated that currently, only 45 per cent of people had received even their first dose of a COVID-19 vaccine, while an increasingly more alarming rate of just 26 per cent received their second dose.
The mobile vaccination station, which is the first service of its’ kind in the state represents a promising opportunity to increase vaccine uptake amongst groups of people who otherwise may not have access to the vaccine and includes easy accessibility for people with disabilities.
Full article:
The Age: The Age: ‘Jabba the Bus’ to take regional vaccination drive onto the road
The Age: ‘The moment you walk in through those doors your healing starts’: Victoria leading the race on Indigenous vaccination
Data released by the federal government has highlighted the widening gap between fully vaccinated Indigenous Australians and the overall population, and the direct impact COVID-19 will have on First Nations people if Australia eases restrictions once 70 or 80 per cent of adults are vaccinated.
Historically, Australia’s Aboriginal community has been heavily impacted by the effects of widespread viral infections such as measles, smallpox and the Spanish Flu and this article highlights the impact low COVID-19 vaccination rates could have on our First Nations people.
Despite the slow rollout, Victoria is leading the way in terms of vaccination rates amongst the Indigenous population with 43% of people fully vaccinated against COVID-19, more than double that of the non-Indigenous population in Victoria at 26%.
According to Jeroen Weimar, the COVID-19 response commander in Victoria, the states’ success with facilitating a competent roll out initiative amongst the Indigenous communities can be attributed to joint efforts and strong partnerships.
लेख को पूरा पढ़ने के लिए कृपया नीचे दिए गए लिंक पर क्लिक करें।
The Age: ‘The moment you walk in through those doors your healing starts’: Victoria leading the race on Indigenous vaccination
WHO: Safety profile of nOPV2 vaccine
In an attempt to implement a global eradication initiative of the polio virus, the first type 2 novel oral polio vaccine (nOPV2) became the first vaccine to be authorised for use under the WHO Emergency Use Listing (EUL) apparatus. However, the current nOPV2 vaccine presents an increased risk of type 2 circulating vaccine-derived polioviruses (cVDPV2), especially in communities with low immunization rates. African countries continue to be amongst the most impacted by this potentially lethal virus. Consequentially, the use of the nOPV2 is currently restricted and SAGE recommended that an independent safety monitoring group be established (GACVS) and maintain thorough safety observations during the entire period of the EUL.
Under the current EUL, there is a 2 phase roll out of the nOPV2 vaccine. With phase 1, countries must first meet stringent initial use criteria and verification requirements including continuous flaccid paralysis (AFP) monitoring to attain approval for use. Following this, phase 2 supports the use of the nOPV2 vaccine as a standard response for cVDPV2 outbreaks.
Following rigorous safety criteria, as of 9 June 2021, 7 countries have received approval for use authorisation of the nOPV2 vaccine and 25 countries are still pending. Majority of the nOPV2 doses thus far have been administered in Nigeria (17 899 130) and Liberia (853 279) amongst children 5 years of age and under in the form of two oral vaccine drops. GACVS is working closely with the Liberian and Nigerian governments to implement AESI surveillance and ongoing AFP data to ensure the safety and effectiveness of the vaccine in preventing polio infection. Current preliminary data analysis did not indicate elevated safety issues associated with the nOPV2 vaccine, however GACVS members have stressed that prolonged, comprehensive surveillance is imperative to signal imminent safety concerns.
To read the extract in full, please click on the link below:
WHO: Safety profile of nOPV2 vaccine